{
    "id": "5c6df86b7c78d69471000045",
    "question": "Is baricitinib effective for rheumatoid arthritis?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer whether baricitinib is effective for rheumatoid arthritis, we need to understand what baricitinib is and how it works. Baricitinib is a Janus kinase (JAK) inhibitor that specifically targets the JAK1, JAK2, and JAK3 enzymes. It is used to treat rheumatoid arthritis (RA) and other inflammatory conditions. According to the provided documents, JAK inhibitors like baricitinib have been shown to be effective in treating RA by blocking the signaling of common gamma chain-containing cytokines, such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which play a crucial role in lymphocyte activation, function, and proliferation. This mechanism of action is consistent with the therapeutic effects of baricitinib in treating RA. Additionally, baricitinib has been shown to reduce C-reactive protein levels and slow disease progression in clinical trials. Therefore, based on the available evidence, baricitinib is effective for the treatment of rheumatoid arthritis.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_4098",
            "title": "Pharmacology_Katzung",
            "content": "Shima Y et al: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49:2408. Smolen J et al: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann Rheum Dis 2009;68:797. Spies CM et al: Prednisone chronotherapy. Clin Exp Rheumatol 2011; 29(Suppl 68):5. Strober B et al: Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013;169:5. Tanaka T, Ogata A, Narazaki M: Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010;6:6. Teng GG, Turkiewicz AM, Moreland LW: Abatacept: A costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005;5:1245."
        },
        {
            "id": "Pharmacology_Katzung_4091",
            "title": "Pharmacology_Katzung",
            "content": "Bannwarth B, Kostine M, Poursac N: A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2013;9:6. Besada E, Koldingsnes W, Nossent J: Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: A case review analysis from a single center. QJM 2012;105:6. Bongartz T et al: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275. Bosello S et al: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010;12:R54. Conklyn M et al: The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 2004;76:6."
        },
        {
            "id": "Pharmacology_Katzung_4093",
            "title": "Pharmacology_Katzung",
            "content": "Emery P et al: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis 2008;67:1516. Emery P et al: The impact of T-cell co-stimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept. Ann Rheum Dis 2010;69:510. Feagan BG et al: The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007;102:4. Fleischmann R et al: Review of head-to-head study designs in rheumatoid arthritis. Semin Arthritis Rheum 2016;46:279. Furst DE: Rational use of disease-modifying antirheumatic drugs. Drugs 1990;39:19. Furst DE et al: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72."
        },
        {
            "id": "Pharmacology_Katzung_4095",
            "title": "Pharmacology_Katzung",
            "content": "Khanna D et al: Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630. Kobayashi K et al: Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 2009;48:15. Kremer J: Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370. Landew\u00e9 R et al: Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:1. Maurizio Cutolo: The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: Latest findings and clinical potential. Ther Adv Musculoskelet Dis 2013;5:1."
        },
        {
            "id": "Pharmacology_Katzung_4096",
            "title": "Pharmacology_Katzung",
            "content": "Maurizio Cutolo: The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: Latest findings and clinical potential. Ther Adv Musculoskelet Dis 2013;5:1. Mease P et al: Abatacept in the treatment of patients with psoriatic arthritis: results of a double-blind, randomized, placebo-controlled phase 2 trial. Arthritis Rheum 2011;63:939. Mease PJ et al: Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:1. Nadashkevich O et al: A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006;25. \u00d8rum M et al: Beneficial effect of infliximab on refractory sarcoidosis. Dan Med J 2012;59:12. Papoutsaki M et al: Infliximab in psoriasis and psoriatic arthritis. BioDrugs 2013;27(Suppl 1):13."
        },
        {
            "id": "Pharmacology_Katzung_4100",
            "title": "Pharmacology_Katzung",
            "content": "Westhovens R et al: Clinical efficacy and safety of abatacept in methotrexate-na\u00efve patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870. Westhovens R et al: Disease remission is achieved within two years in over half of methotrexate naive patients with early erosive rheumatoid arthritis (RA) treated with abatacept plus MTX: results from the AGREE trial (abstract 638). Arthritis Rheum 2009;60:S239. Yokota S, Kishimoto T: Tocilizumab: Molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol 2010;6:5. Zouali M, Uy EA: Belimumab therapy in systemic lupus erythematosus. BioDrugs 2013;27:3. Chandrasekharan NV et al: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926."
        },
        {
            "id": "Pharmacology_Katzung_4037",
            "title": "Pharmacology_Katzung",
            "content": "3. Indications: Tofacitinib was originally developed to prevent solid organ allograft rejection. It has also been tested for the treatment of inflammatory bowel disease, spondyloarthritis, psoriasis, and dry eyes. To date, tofacitinib is approved in the United States for the treatment of adult patients with moderately to severely active RA who have failed or are intolerant to methotrexate. It is not approved in Europe for this indication. It can be used as a monotherapy or in combination with other csDMARDs, including methotrexate. Ongoing studies are evaluating its role in other rheumatic diseases such as PsA, psoriasis, and JIA. 4."
        },
        {
            "id": "Immunology_Janeway_4064",
            "title": "Immunology_Janeway",
            "content": "Antibodies and recombinant proteins against the pro-inflammatory cytokine IL-1 and its receptor have not proved as effective as TNF-\u03b1 blockade for treating rheumatoid arthritis in humans, despite being equally powerful in animal models of arthritis. An antibody against the cytokine IL-1 has been licensed for clinical use against the hereditary autoinflammatory disease Muckle\u2013 Wells syndrome (see Section 13-9), and blockade of the IL-1\u03b2 receptor by the recombinant protein anakinra (Kineret) has also proven useful in adults with moderate to severe rheumatoid arthritis. Another cytokine antagonist in clinical use is the humanized antibody tocilizumab; by virtue of being directed against the IL-6 receptor, it blocks the effects of the pro-inflammatory cytokine IL-6. This seems to be as effective as anti-TNF-\u03b1 in patients with rheumatoid arthritis and also shows promise in treating systemic-onset juvenile idiopathic arthritis, an autoinflammatory condition."
        },
        {
            "id": "Pharmacology_Katzung_4099",
            "title": "Pharmacology_Katzung",
            "content": "Teng GG, Turkiewicz AM, Moreland LW: Abatacept: A costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005;5:1245. Turner D: Severe acute ulcerative colitis: the pediatric perspective. Dig Dis 2009;27:3 van Gurp EA et al: The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation 2009;87:1. Weinblatt M et al: Adalimumab, a fully human anti-tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003;48:35. Weinblatt ME et al: Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65:1."
        },
        {
            "id": "Pharmacology_Katzung_4097",
            "title": "Pharmacology_Katzung",
            "content": "\u00d8rum M et al: Beneficial effect of infliximab on refractory sarcoidosis. Dan Med J 2012;59:12. Papoutsaki M et al: Infliximab in psoriasis and psoriatic arthritis. BioDrugs 2013;27(Suppl 1):13. Plosker G, Croom K: Sulfasalazine: A review of its use in the management of rheumatoid arthritis. Drugs 2006;65:1825. Riese RJ, Krishnaswami S, Kremer J: Inhibition of JAK kinases in patients with rheumatoid arthritis: Scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010;24:4. Ruperto N et al: Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 2:372. Scott DL, Kingsley GH: Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704. Shima Y et al: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49:2408."
        },
        {
            "id": "Pharmacology_Katzung_7183",
            "title": "Pharmacology_Katzung",
            "content": "3. Select a specific therapeutic objective: A therapeutic objective should be chosen for each of the pathophysiologic processes defined in the preceding step. In a patient with rheumatoid arthritis, relief of pain by reduction of the inflammatory process is one of the major therapeutic goals that identifies the drug groups that should be considered. Arresting the course of the disease process in rheumatoid arthritis is a different therapeutic goal, which might lead to consideration of additional drug groups and prescriptions. 4."
        },
        {
            "id": "Pharmacology_Katzung_4094",
            "title": "Pharmacology_Katzung",
            "content": "Furst DE et al: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72. Gabay C et al: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial. Lancet 2013;4:381. Genovese MC et al: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor \u03b1 inhibition. N Engl J Med 2005;353:1114. Genovese MC et al: Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:10. Griffiths CE et al: Comparison of ustekinumab and etanercept for moderate-tosevere psoriasis. N Engl J Med 2010;362:118. Keystone E et al: Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008;59:785."
        },
        {
            "id": "Pharmacology_Katzung_4090",
            "title": "Pharmacology_Katzung",
            "content": "Slawson D: NSAID Use associated with increased risk of serious bleeding and CV events after MI. Am Fam Physician 2015;92;60. U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Available at: www.fda.gov/ Drugs/DrugSafety/ucm451800.htm. Vane J, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89. http://www.rheumatology. org/I-Am-A/Patient-Caregiver/Treatments/NSAIDs. Atzeni F et al: Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 2007;6:8. Bannwarth B, Kostine M, Poursac N: A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 2013;9:6."
        },
        {
            "id": "InternalMed_Harrison_25254",
            "title": "InternalMed_Harrison",
            "content": "Tofacitinib Tofacitinib is a small-molecule inhibitor that primarily inhibits JAK1 and JAK3, which mediate signaling of the receptors for the common \u03b3-chain-related cytokines IL-2, -4, -7, -9, -15, and -21 as well as IFN-\u03b3 and IL-6. These cytokines all play roles in promoting T and B cell activation as well as inflammation. Tofacitinib, an oral agent, has been shown in randomized, placebo-controlled clinical trials to improve the signs and symptoms of RA significantly over placebo. Major adverse events include elevated serum transaminases indicative of liver injury, neutropenia, increased cholesterol levels, and elevation in serum creatinine. Its use is also associated with an increased risk of infections. Tofacitinib can be used as mono-therapy or in combination with methotrexate. APPROACH TO THE PATIENT:"
        },
        {
            "id": "Pharmacology_Katzung_3987",
            "title": "Pharmacology_Katzung",
            "content": "placebo than in those treated with abatacept over 1 year. Abatacept has been tested in other rheumatic diseases like SLE, primary Sj\u00f6gren\u2019s syndrome, type 1 diabetes, inflammatory bowel disease, and psoriasis vulgaris, but the most beneficial effects were seen in psoriatic arthritis (PsA) patients."
        },
        {
            "id": "Pharmacology_Katzung_4011",
            "title": "Pharmacology_Katzung",
            "content": "1. Mechanism of Action: Tocilizumab, a newer biologic humanized antibody, binds to soluble and membrane-bound IL-6 receptors, and inhibits the IL-6-mediated signaling via these receptors. IL-6 is a proinflammatory cytokine produced by different cell types including T cells, B cells, monocytes, fibroblasts, and synovial and endothelial cells. IL-6 is involved in a variety of physiologic processes such as T-cell activation, hepatic acute-phase protein synthesis, and stimulation of the inflammatory processes involved in diseases such as RA and systemic sclerosis (SSc). In a phase 4 superiority study, tocilizumab monotherapy was superior to adalimumab monotherapy for reduction of signs and symptoms of rheumatoid arthritis in patients with incomplete response to MTX. 2."
        },
        {
            "id": "Pharmacology_Katzung_4001",
            "title": "Pharmacology_Katzung",
            "content": "3. Dosage and Indications: It is recommended to start treatment with 7.5 mg weekly. According to patient response, methotrexate is increased to the most common dosing regimen for the treatment of RA, which is 15\u201325 mg weekly. Notably there is an increased effect up to 30\u201335 mg weekly, although with increased toxicity. The drug decreases the rate of appearance of new erosions. Evidence supports its use in juvenile chronic arthritis, and it has been used in psoriasis, PA, AS, polymyositis, dermatomyositis, Wegener\u2019s granulomatosis, giant cell arteritis, SLE, and vasculitis. 4."
        },
        {
            "id": "Pharmacology_Katzung_4087",
            "title": "Pharmacology_Katzung",
            "content": "Hatemi G et al: EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 2008;67:1656. Hellman DB, Imboden JB Jr: Rheumatologic, immunologic, and allergic disorders. In: Papadakis MA, McPhee ST (editors). Current Medical Diagnosis & Treatment, 2017. McGraw-Hill Education, 2017. Chan FK et al: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104. Clevers H: Colon cancer\u2014Understanding how NSAIDs work. N Engl J Med 2006;354:761. Deeks JJ, Smith LA, Bradley MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: Systematic review of randomised controlled trials. BMJ 2002;325:619. Furst DE et al: Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: A 12 week multi-center, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002;29:436."
        },
        {
            "id": "Pharmacology_Katzung_4042",
            "title": "Pharmacology_Katzung",
            "content": "3. Indications: Anakinra is approved for the treatment of moderately to severely active RA in adult patients, but it is rarely used for this indication. However, anakinra is the drug of choice for CAPS, particularly the neonatal-onset multisystem inflammatory disease (NOMID) subtype. Anakinra is effective in gout (see below) and is used for other diseases including Beh\u00e7et\u2019s disease and adult onset JIA. Its use for giant cell arteritis is controversial. 1. Mechanism of Action: Canakinumab is a human IgG1/\u03ba monoclonal antibody against IL-1\u03b2. It forms a complex with IL-1\u03b2, preventing its binding to IL-1 receptors. 2."
        },
        {
            "id": "InternalMed_Harrison_25252",
            "title": "InternalMed_Harrison",
            "content": "Tocilizumab Tocilizumab is a humanized monoclonal antibody directed against the membrane and soluble forms of the IL-6 receptor. IL-6 is a proinflammatory cytokine implicated in the pathogenesis of RA, with detrimental effects on both joint inflammation and damage. IL-6 binding to its receptor activates intracellular signaling pathways that affect the acute-phase response, cytokine production, and osteoclast activation. Clinical trials attest to the clinical efficacy of tocilizumab therapy for RA, both as monotherapy and in combination with methotrexate and other DMARDs. Tocilizumab has been associated with an increased risk of infection, neutropenia, and thrombocytopenia; however, the hematologic abnormalities appear to be reversible upon stopping the drug. In addition, this agent has been shown to increase LDL cholesterol; however, it is not known as yet if this effect on lipid levels increases the risk for development of atherosclerotic disease."
        },
        {
            "id": "Immunology_Janeway_4035",
            "title": "Immunology_Janeway",
            "content": "example, tofacitinib inhibits JAK3, interfering with signaling by IL-2 and IL-4, and somewhat more weakly JAK1, interfering with signaling by IL-6. Tofacitinib is approved for treatment of rheumatoid arthritis. Ruxolitinib inhibits JAK1 and JAK2 and has been approved for treating myelofibrosis, an abnormal proliferation of bone marrow progenitor cells that causes fibrosis."
        },
        {
            "id": "InternalMed_Harrison_25244",
            "title": "InternalMed_Harrison",
            "content": "of RA, slow radiographic progression of joint damage, and improve physical function and quality of life. Anti-TNF drugs are typically used in combination with background methotrexate therapy. This combination regimen, which affords maximal benefit in many cases, is often the next step for treatment of patients with an inadequate response to methotrexate therapy. Etanercept, adalimumab, certolizumab pegol, and golimumab have also been approved for use as monotherapy."
        },
        {
            "id": "InternalMed_Harrison_24658",
            "title": "InternalMed_Harrison",
            "content": "Cytokines and Cytokine Inhibitors Several TNF inhibitors are used as biological therapies in the treatment of rheumatoid arthritis; these include monoclonal antibodies, TNF-R Fc fusion proteins, and Fab fragments. Use of anti-TNF-\u03b1 antibody therapies such as adalimumab, infliximab, and golimumab has resulted in clinical improvement in patients with these diseases and has opened the way for targeting TNF-\u03b1 to treat other severe forms of autoimmune and/or inflammatory disease. Blockage of TNF-\u03b1 has been effective in rheumatoid arthritis, psoriasis, Crohn\u2019s disease, and ankylosing spondylitis. Other cytokine inhibitors are recombinant soluble TNF-\u03b1 receptor (R) fused to human Ig and anakinra (soluble IL-1 receptor antagonist, or IL-1ra). The treatment of autoinflammatory syndromes (Table 372e-6) with recombinant IL-1 receptor antagonist can prevent symptoms in these syndromes, because the overproduction of IL-1\u03b2 is a hallmark of these diseases."
        },
        {
            "id": "Pharmacology_Katzung_3986",
            "title": "Pharmacology_Katzung",
            "content": "Indications: Abatacept can be used as monotherapy or in combination with methotrexate or other DMARDs in patients with moderate to severe RA or severe PJIA. It has been tested in combination with methotrexate in early rapidly progressing RA and methotrexate-na\u00efve patients. The combination was superior to methotrexate in achieving minimal disease activity as early as 2 months, significantly inhibiting radiographic progression at 1 year and improving patients\u2019 physical function and symptoms. Such improvement is sustained or improved during the second year. Another trial (ADJUST) tested the effectiveness of abatacept in preventing progression to defined RA in patients with undifferentiated inflammatory arthritis. The results showed that numerically, RA developed in more patients treated with placebo than in those treated with abatacept over 1 year. Abatacept has been tested in other rheumatic diseases like SLE, primary Sj\u00f6gren\u2019s syndrome, type 1 diabetes, inflammatory bowel disease, and"
        },
        {
            "id": "Immunology_Janeway_4502",
            "title": "Immunology_Janeway",
            "content": "Fig. A.42 In vivo administration of antibodies is an effective therapeutic. The cytokine TNF-\u03b1 contributes to chronic inflammation in a range of conditions, including rheumatoid arthritis, by binding to and triggering signaling of the TNF receptor (TNFR). To treat these conditions, a fusion protein consisting of the constant-region domains of human IgG1 is fused to the extracellular portion of the TNFR, creating a therapeutic known as etanercept. When administered to patients, this fusion protein is effective at binding TNF-\u03b1 and preventing it from triggering TNFR signaling, thereby reducing inflammation."
        },
        {
            "id": "Pharmacology_Katzung_3999",
            "title": "Pharmacology_Katzung",
            "content": "of action. Methotrexate has direct inhibitory effects on proliferation and stimulates apoptosis in immune-inflammatory cells. Additionally, it inhibits proinflammatory cytokines linked to rheumatoid synovitis."
        },
        {
            "id": "Pharmacology_Katzung_4035",
            "title": "Pharmacology_Katzung",
            "content": "1. Mechanism of Action: Tofacitinib is a targeted synthetic small molecule (tsDMARD) that selectively inhibits all members of the Janus kinase (JAK; see Chapter 2) family to varying degrees. At therapeutic doses, tofacitinib exerts its effect mainly by inhibiting JAK3, and to a lesser extent JAK1, hence interrupting the JAK-STAT signaling pathway. This pathway plays a major role in the pathogenesis of autoimmune diseases including RA. The JAK3/JAK1 complex is responsible for signal transduction from the common \u03b3-chain receptor (IL2RG) for IL-2, -4, -7, -9, -15, and -21, which subsequently influences transcription of several genes that are crucial for the differentiation, proliferation, and function of NK cells and T and B lymphocytes. In addition, JAK1 (in combination with other JAKs) controls signal transduction from IL-6 and interferon receptors. RA patients receiving tofacitinib rapidly reduce C-reactive protein. 2."
        },
        {
            "id": "Pharmacology_Katzung_3948",
            "title": "Pharmacology_Katzung",
            "content": "The glucocorticoids also have powerful anti-inflammatory effects and when first introduced were considered to be the ultimate answer to the treatment of inflammatory arthritis. Although there are data indicating that low-dose corticosteroids have disease-modifying properties, particularly in the early phase of RA, their toxicity makes them less favored than other medications, when it is possible to use the others. However, the glucocorticoids continue to have a significant role in the long-term treatment of arthritis. Another important group of agents are characterized as disease-modifying anti-rheumatic drugs (DMARDs) including biologics (a subset of the DMARDs). They decrease inflammation, improve symptoms, and slow the bone damage associated with RA. They affect more basic inflammatory mechanisms than do glucocorticoids or the NSAIDs. They may also be more toxic than those alternative medications."
        },
        {
            "id": "Pharmacology_Katzung_4036",
            "title": "Pharmacology_Katzung",
            "content": "2. Pharmacokinetics: The recommended dose of tofacitinib in the treatment of RA is 5 mg twice daily; there is a clear trend to increased response (and increased toxicity) at double this dose. In 2016, the FDA approved extended-release (XR) tofacitinib citrate 11 mg tablets for once-daily treatment. Tofacitinib has an absolute oral bioavailability of 74%, high-fat meals do not affect the AUC, and the elimination half-life is about 3 hours. Metabolism (of 70%) occurs in the liver, mainly by CYP3A4 and to a lesser extent by CYP2C19. The remaining 30% is excreted unchanged by the kidneys. Patients taking CYP enzyme inhibitors and those with moderate hepatic or renal impairment require dose reduction to 5 mg once daily. It should not be given to patients with severe hepatic disease. 3."
        },
        {
            "id": "Immunology_Janeway_4061",
            "title": "Immunology_Janeway",
            "content": "Anti-TNF therapy was the first specific biological therapeutic to enter the clinic. Anti-TNF-\u03b1 antibodies induced striking remissions in rheumatoid arthritis (Fig. 16.9) and reduced inflammation in Crohn\u2019s disease, an inflammatory bowel disease (see Section 15-23). Two types of established biologics are used to antagonize TNF-\u03b1 in clinical practice. The first type comprises the antiTNF-\u03b1 antibodies, such as infliximab and adalimumab, which bind to TNF-\u03b1 and block its activity. The second type is a recombinant human TNF receptor (TNFR) subunit p75\u2013Fc fusion protein called etanercept, which also binds TNF-\u03b1, neutralizing its activity. These are extremely potent anti-inflammatory agents, and the number of diseases in which they have been shown to be effective is growing as further clinical trials are performed. In addition to rheumatoid arthritis, the rheumatic diseases ankylosing spondylitis, psoriatic arthropathy, and juvenile idiopathic arthritis (other than the systemic-onset subset)"
        },
        {
            "id": "Pharmacology_Katzung_2001",
            "title": "Pharmacology_Katzung",
            "content": "A. Inflammation Aspirin has been used to treat arthritis of all types for approximately 100 years, but its mechanism of action\u2014inhibition of COX activity\u2014was not discovered until 1971. COX-2 appears to be the form of the enzyme most associated with cells involved in the inflammatory process, although, as outlined above, COX-1 also contributes significantly to prostaglandin biosynthesis during inflammation. Aspirin and other anti-inflammatory agents that inhibit COX are discussed in Chapter 36. B. Rheumatoid Arthritis In rheumatoid arthritis, immune complexes are deposited in the affected joints, causing an inflammatory response that is amplified by eicosanoids. Lymphocytes and macrophages accumulate in the synovium, whereas leukocytes localize mainly in the synovial fluid."
        },
        {
            "id": "InternalMed_Harrison_22986",
            "title": "InternalMed_Harrison",
            "content": "Tofacitinib is an oral inhibitor of Janus kinases 1, 3, and, to a lesser extent, 2. It is expected to block signaling involving common gamma chain\u2013containing cytokines including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. These cytokines are integral to lymphocyte activation, function, and proliferation. It is effective in moderate to severe UC in clinical trials."
        }
    ],
    "scores": [
        0.03523989983479439,
        0.0340128480468602,
        0.03391206494654771,
        0.03390054998176171,
        0.03360033846956514,
        0.030954237563207698,
        0.028684058882078686,
        0.028488687267330934,
        0.027128055361937783,
        0.02701807995925643,
        0.026869983426046018,
        0.026287438052143935,
        0.02507593416684326,
        0.024537785060845824,
        0.02412146307241983,
        0.023353644072822154,
        0.021864731159498788,
        0.021326565308204204,
        0.021265721865977857,
        0.020819397993311037,
        0.01960972796308757,
        0.01949381072391662,
        0.01939369950878902,
        0.01916024935826916,
        0.018924960400290153,
        0.018513421145000094,
        0.01846494213750851,
        0.017630683575626353,
        0.017238828055637763,
        0.0168928470455188,
        0.01597082494969819,
        0.015899949723479134
    ]
}